LAVA Therapeutics is focused on developing its Gammabody® platform to transform cancer therapy through bispecific gamma delta T cell engagers that activate Vγ9Vδ2 T cells, selectively targeting and killing cancer cells while minimizing toxicity to healthy tissues
LAVA Therapeutics is focused on developing its Gammabody® platform to transform cancer therapy through bispecific gamma delta T cell engagers that activate Vγ9Vδ2 T cells, selectively targeting and killing cancer cells while minimizing toxicity to healthy tissues.